{"id":6061,"date":"2026-05-22T08:00:00","date_gmt":"2026-05-22T05:00:00","guid":{"rendered":"https:\/\/www.clinipower.fi\/?p=6061"},"modified":"2026-03-02T11:49:08","modified_gmt":"2026-03-02T08:49:08","slug":"what-does-mdcg-2019-11-mean-for-health-technology-companies","status":"publish","type":"post","link":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/","title":{"rendered":"What does MDCG 2019-11 mean for health technology companies?"},"content":{"rendered":"

MDCG 2019-11<\/strong> is a guidance document from the Medical Device Coordination Group that clarifies clinical evaluation requirements under the Medical Device Regulation (MDR). This guidance establishes standardised procedures for assessing medical device safety and performance and requires health technology companies to implement more rigorous clinical evaluation processes. Understanding these requirements is essential for maintaining regulatory compliance and market access across Europe.<\/p>\n

What is MDCG 2019-11 and why does it matter for health technology companies?<\/h2>\n

MDCG 2019-11 is the official guidance document titled “Guidance on Clinical Evaluation” that interprets clinical evaluation requirements under Regulation (EU) 2017\/745 (MDR). It provides detailed instructions for conducting clinical evaluations, establishing equivalence, and maintaining post-market clinical follow-up for medical devices and healthcare software.<\/p>\n

This guidance matters significantly because it standardises how clinical evaluations<\/strong> must be conducted across all EU member states. Previously, interpretations of clinical evaluation requirements varied among notified bodies and regulatory authorities, creating uncertainty for manufacturers. The guidance establishes clear expectations for clinical evidence, documentation standards, and assessment methodologies.<\/p>\n

For health technology companies, MDCG 2019-11 affects product development timelines, regulatory strategies, and resource allocation. Companies must demonstrate clinical safety and performance through robust clinical evidence, whether generated through clinical investigations or established through equivalence to predicate devices. The guidance also emphasises the importance of continuous clinical evaluation throughout a device’s lifecycle.<\/p>\n

Software as a Medical Device (SaMD) developers face particular challenges, as the guidance clarifies how clinical evaluation principles apply to digital health technologies. This includes requirements for clinical evidence proportionate to the software’s risk classification and intended use.<\/p>\n

How does MDCG 2019-11 change clinical evaluation requirements for medical devices?<\/h2>\n

The guidance introduces stricter documentation requirements, enhanced equivalence criteria, and more comprehensive post-market surveillance obligations compared with previous Medical Device Directive (MDD) practices. Companies must now provide detailed clinical evaluation plans, systematic literature reviews, and robust clinical evidence demonstrating device safety and performance.<\/p>\n

Key changes include enhanced equivalence demonstration<\/strong> requirements. Under the MDD, establishing equivalence was often straightforward, but MDCG 2019-11 demands comprehensive technical, biological, and clinical comparisons. Companies must demonstrate that their device has the same intended purpose, similar technology, and equivalent safety and performance characteristics as the predicate device.<\/p>\n

The guidance mandates systematic literature reviews following specific methodologies. These reviews must be comprehensive, transparent, and regularly updated. Companies can no longer rely on limited literature searches or cherry-picked studies to support their clinical evaluation.<\/p>\n

Post-market clinical follow-up (PMCF) requirements have been strengthened significantly. Companies must establish PMCF systems that actively collect clinical data throughout the device lifecycle. This includes proactive data collection, not merely passive surveillance, and regular updates to the clinical evaluation based on emerging evidence.<\/p>\n

For higher-risk devices, the guidance emphasises the need for clinical investigations when equivalence cannot be established or when existing clinical evidence is insufficient. This represents a shift from the previous approach, in which clinical investigations were often avoided.<\/p>\n

What practical steps should health technology companies take to comply with MDCG 2019-11?<\/h2>\n

Companies should begin by conducting gap analyses comparing current clinical evaluation processes with MDCG 2019-11 requirements. This involves reviewing existing clinical evaluation reports, equivalence demonstrations, and PMCF systems to identify areas requiring updates or complete overhauls.<\/p>\n

Immediate actions include updating clinical evaluation procedures<\/strong> and templates to align with the guidance’s structure and content requirements. Companies need revised clinical evaluation plans, systematic literature review protocols, and PMCF plans that meet the new standards. Documentation must be more detailed and transparent than previous MDD submissions.<\/p>\n

Team training is a critical implementation step. Clinical affairs professionals, regulatory personnel, and quality assurance teams require education on the new requirements. Many companies benefit from external training or consulting support to ensure proper understanding and implementation.<\/p>\n

Resource planning must account for the increased clinical evaluation workload. The guidance requires more comprehensive documentation, regular updates, and ongoing clinical data collection. Companies should budget for additional clinical affairs resources or external support to manage these requirements effectively.<\/p>\n

Timeline considerations are crucial for products approaching regulatory submission. Clinical evaluation updates can take several months, particularly for complex devices or those requiring new clinical investigations. Companies should integrate these requirements into their product development schedules early.<\/p>\n

We assist health technology companies in navigating these regulatory changes through our quality and regulatory services. Our team provides comprehensive support for clinical evaluations, technical documentation development, and regulatory compliance strategies tailored to your specific product requirements and market objectives.<\/p>\n","protected":false},"excerpt":{"rendered":"

Discover how MDCG 2019-11 transforms clinical evaluation requirements for medical devices and health technology companies across Europe. […]<\/p>\n

Read More… from What does MDCG 2019-11 mean for health technology companies?<\/span><\/a><\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-6061","post","type-post","status-publish","format-standard","hentry","category-laatu-ja-saantely"],"acf":[],"gutentor_comment":0,"yoast_head":"\nWhat does MDCG 2019-11 mean for health technology companies? - Clinipower Finland Oy<\/title>\n<meta name=\"description\" content=\"Learn how MDCG 2019-11 guidance transforms clinical evaluation requirements for medical devices. Essential compliance steps for health technology companies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What does MDCG 2019-11 mean for health technology companies? - Clinipower Finland Oy\" \/>\n<meta property=\"og:description\" content=\"Learn how MDCG 2019-11 guidance transforms clinical evaluation requirements for medical devices. Essential compliance steps for health technology companies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinipower Finland Oy\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T05:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Sylvia Syv\u00e4nen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sylvia Syv\u00e4nen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/what-does-mdcg-2019-11-mean-for-health-technology-companies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/what-does-mdcg-2019-11-mean-for-health-technology-companies\\\/\"},\"author\":{\"name\":\"Sylvia Syv\u00e4nen\",\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#\\\/schema\\\/person\\\/82701851d0878467369e02283af1af59\"},\"headline\":\"What does MDCG 2019-11 mean for health technology companies?\",\"datePublished\":\"2026-05-22T05:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/what-does-mdcg-2019-11-mean-for-health-technology-companies\\\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#organization\"},\"articleSection\":[\"Laatu ja s\u00e4\u00e4ntely\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/what-does-mdcg-2019-11-mean-for-health-technology-companies\\\/\",\"url\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/what-does-mdcg-2019-11-mean-for-health-technology-companies\\\/\",\"name\":\"What does MDCG 2019-11 mean for health technology companies? - Clinipower Finland Oy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#website\"},\"datePublished\":\"2026-05-22T05:00:00+00:00\",\"description\":\"Learn how MDCG 2019-11 guidance transforms clinical evaluation requirements for medical devices. Essential compliance steps for health technology companies.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/what-does-mdcg-2019-11-mean-for-health-technology-companies\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/\",\"name\":\"Clinipower Finland Oy\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#organization\",\"name\":\"Clinipower Oy\",\"url\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Clinipower Oy\"},\"image\":{\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.clinipower.fi\\\/en\\\/#\\\/schema\\\/person\\\/82701851d0878467369e02283af1af59\",\"name\":\"Sylvia Syv\u00e4nen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f08683e6f46efa3950a6721f89c14d82302c8228e0358ef04fd1767ac70dae6c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f08683e6f46efa3950a6721f89c14d82302c8228e0358ef04fd1767ac70dae6c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f08683e6f46efa3950a6721f89c14d82302c8228e0358ef04fd1767ac70dae6c?s=96&d=mm&r=g\",\"caption\":\"Sylvia Syv\u00e4nen\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"What does MDCG 2019-11 mean for health technology companies? - Clinipower Finland Oy","description":"Learn how MDCG 2019-11 guidance transforms clinical evaluation requirements for medical devices. Essential compliance steps for health technology companies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/","og_locale":"en_US","og_type":"article","og_title":"What does MDCG 2019-11 mean for health technology companies? - Clinipower Finland Oy","og_description":"Learn how MDCG 2019-11 guidance transforms clinical evaluation requirements for medical devices. Essential compliance steps for health technology companies.","og_url":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/","og_site_name":"Clinipower Finland Oy","article_published_time":"2026-05-22T05:00:00+00:00","author":"Sylvia Syv\u00e4nen","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sylvia Syv\u00e4nen","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/#article","isPartOf":{"@id":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/"},"author":{"name":"Sylvia Syv\u00e4nen","@id":"https:\/\/www.clinipower.fi\/en\/#\/schema\/person\/82701851d0878467369e02283af1af59"},"headline":"What does MDCG 2019-11 mean for health technology companies?","datePublished":"2026-05-22T05:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/"},"wordCount":733,"publisher":{"@id":"https:\/\/www.clinipower.fi\/en\/#organization"},"articleSection":["Laatu ja s\u00e4\u00e4ntely"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/","url":"https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/","name":"What does MDCG 2019-11 mean for health technology companies? - Clinipower Finland Oy","isPartOf":{"@id":"https:\/\/www.clinipower.fi\/en\/#website"},"datePublished":"2026-05-22T05:00:00+00:00","description":"Learn how MDCG 2019-11 guidance transforms clinical evaluation requirements for medical devices. Essential compliance steps for health technology companies.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.clinipower.fi\/en\/what-does-mdcg-2019-11-mean-for-health-technology-companies\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.clinipower.fi\/en\/#website","url":"https:\/\/www.clinipower.fi\/en\/","name":"Clinipower Finland Oy","description":"","publisher":{"@id":"https:\/\/www.clinipower.fi\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.clinipower.fi\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.clinipower.fi\/en\/#organization","name":"Clinipower Oy","url":"https:\/\/www.clinipower.fi\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.clinipower.fi\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Clinipower Oy"},"image":{"@id":"https:\/\/www.clinipower.fi\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.clinipower.fi\/en\/#\/schema\/person\/82701851d0878467369e02283af1af59","name":"Sylvia Syv\u00e4nen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f08683e6f46efa3950a6721f89c14d82302c8228e0358ef04fd1767ac70dae6c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f08683e6f46efa3950a6721f89c14d82302c8228e0358ef04fd1767ac70dae6c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f08683e6f46efa3950a6721f89c14d82302c8228e0358ef04fd1767ac70dae6c?s=96&d=mm&r=g","caption":"Sylvia Syv\u00e4nen"}}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"Sylvia Syv\u00e4nen","author_link":"https:\/\/www.clinipower.fi\/en\/author\/sylvia\/"},"_links":{"self":[{"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/posts\/6061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/comments?post=6061"}],"version-history":[{"count":1,"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/posts\/6061\/revisions"}],"predecessor-version":[{"id":6154,"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/posts\/6061\/revisions\/6154"}],"wp:attachment":[{"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/media?parent=6061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/categories?post=6061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.clinipower.fi\/en\/wp-json\/wp\/v2\/tags?post=6061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}